in vitro selection of autochthonous lactic acid bacterium from clownfish Amphiprion ocellaris.

Made available in DSpace on 2020-01-14T18:15:43Z (GMT). No. of bitstreams: 1 Paixoetal2019AquacultureResearchprobioticopalhaco.pdf: 277299 bytes, checksum: e2bf3490635b77099ad7ab5624969887 (MD5) Previous issue date: 2019bitstream/item/208746/1/Paix-o-et-al-2019-Aquaculture-Research-probiotico-palhaco.pd

Dietary supplementation of Probiotic Enterococcus faecium improve resistance in Arapaima gigas against Aeromonas hydrophila.

This study evaluated the mortality rate, histopathology and haematological param-eters of Arapaima gigas against Aeromonas hydrophila after 68 days of dietary probiotic supplementation with autochthonous bacterium Enterococcus faecium. Three experi-ments were carried out: the first assay evaluated the lethality of A. hydrophila, the second and the third assay evaluated the fish supplemented subjected to A. hydrophilalethal dose 30% (106 CFU ml−1) and lethal dose 100% (108CFU ml−1) respectively. The clinical signs, blood changes, histopathological alterations and mortalities were evalu-ated. At the first experiment, the concentrations of 106 and 108CFU.mL−1 with A. hy-drophila caused 33% and 100% of mortality. The A. hydrophila infection provoked clinical signs such as dark skin, ulceration, haemorrhage, pale gills and liver, hepatic alterations, hyperaemia, hepatic cord breakdown, cellular deforming, lipid degener-ation and necrosis. In the second experiment, no mortality occurred onto fish fed with probiotic. Furthermore, in the third experiment, fish submitted to probiotic sup-plementation showed reduction in mortality of 75% compared with the control and fish fed with probiotic diets at 108CFU g−1 not presented any clinical signs. For these reasons, Arapaima gigas juveniles previously submitted to probiotic supplementation with E. faecium (108CFU g−1) shows better physiological and immunological response, improving resistance against A. hydrophila infection

Influence of single and binary doping of strontium and lithium on in vivo biological properties of bioactive glass scaffolds

Effects of strontium and lithium ion doping on the biological properties of bioactive glass (BAG) porous scaffolds have been checked in vitro and in vivo. BAG scaffolds were prepared by conventional glass melting route and subsequently, scaffolds were produced by evaporation of fugitive pore formers. After thorough physico-chemical and in vitro cell characterization, scaffolds were used for pre-clinical study. Soft and hard tissue formation in a rabbit femoral defect model after 2 and 4 months, were assessed using different tools. Histological observations showed excellent osseous tissue formation in Sr and Li + Sr scaffolds and moderate bone regeneration in Li scaffolds. Fluorochrome labeling studies showed wide regions of new bone formation in Sr and Li + Sr doped samples as compared to Li doped samples. SEM revealed abundant collagenous network and minimal or no interfacial gap between bone and implant in Sr and Li + Sr doped samples compared to Li doped samples. Micro CT of Li + Sr samples showed highest degree of peripheral cancellous tissue formation on periphery and cortical tissues inside implanted samples and vascularity among four compositions. Our findings suggest that addition of Sr and/or Li alters physico-chemical properties of BAG and promotes early stage in vivo osseointegration and bone remodeling that may offer new insight in bone tissue engineering

Seleção de bactéria espécie-específica com potencial probiótico para o tambaqui.

bitstream/item/186690/1/DOC-217.pd

Composite polymer-bioceramic scaffolds with drug delivery capability for bone tissue engineering

Next-generation scaffolds for bone tissue engineering (BTE) should exhibit the appropriate combination of mechanical support and morphological guidance for cell proliferation and attachment while at the same time serving as matrices for sustained delivery of therapeutic drugs and/or biomolecular signals, such as growth factors. Drug delivery from BTE scaffolds to induce the formation of functional tissues, which may need to vary temporally and spatially, represents a versatile approach to manipulating the local environment for directing cell function and/or to treat common bone diseases or local infection. In addition, drug delivery from BTE is proposed to either increase the expression of tissue inductive factors or to block the expression of others factors that could inhibit bone tissue formation. Composite scaffolds which combine biopolymers and bioactive ceramics in mechanically competent 3D structures, including also organic--inorganic hybrids, are being widely developed for BTE, where the affinity and interaction between biomaterials and therapeutic drugs or biomolecular signals play a decisive role in controlling the release rate.This review covers current developments and applications of 3D composite scaffolds for BTE which exhibit the added capability of controlled delivery of therapeutic drugs or growth factors. A summary of drugs and biomolecules incorporated in composite scaffolds and approaches developed to combine biopolymers and bioceramics in composites for drug delivery systems for BTE is presented. Special attention is given to identify the main challenges and unmet needs of current designs and technologies for developing such multifunctional 3D composite scaffolds for BTE. One of the major challenges for developing composite scaffolds for BTE is the incorporation of a drug delivery function of sufficient complexity to be able to induce the release patterns that may be necessary for effective osseointegration, vascularization and bone regeneration. Loading 3D scaffolds with different biomolecular agents should produce a codelivery system with different, predetermined release profiles. It is also envisaged that the number of relevant bioactive agents that can be loaded onto scaffolds will be increased, whilst the composite scaffold design should exploit synergistically the different degradation profiles of the organic and inorganic components.Fil: Mouriño, Viviana Silvia Lourdes. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina; Universitat Erlangen-Nuremberg; Alemania;Fil: Cattalini, Juan Pablo. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina; Universitat Erlangen-Nuremberg; Alemania;Fil: Roether, J.. Universitat Erlangen-Nuremberg; Alemania;Fil: Dubey, P.. Universitat Erlangen-Nuremberg; Alemania;Fil: Roy, I.. Universitat Erlangen-Nuremberg; Alemania;Fil: Boccaccini, A. R.. Universitat Erlangen-Nuremberg; Alemania